Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Change in Receivables (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Change in Receivables for 4 consecutive years, with $27121.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Receivables rose 110.1% to $27121.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$878178.0, a 418.22% decrease, with the full-year FY2024 number at $327530.0, up 205.19% from a year prior.
  • Change in Receivables was $27121.0 for Q3 2025 at bioAffinity Technologies, up from -$541875.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $472017.0 in Q2 2024 to a low of -$541875.0 in Q2 2025.
  • A 4-year average of -$44339.4 and a median of $559.0 in 2022 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: tumbled 42949.02% in 2023, then skyrocketed 57880.48% in 2024.
  • bioAffinity Technologies' Change in Receivables stood at $559.0 in 2022, then crashed by 42949.02% to -$239526.0 in 2023, then rose by 21.53% to -$187964.0 in 2024, then skyrocketed by 114.43% to $27121.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Change in Receivables are $27121.0 (Q3 2025), -$541875.0 (Q2 2025), and -$175460.0 (Q1 2025).